ArticleACR open rheumatology2025
Prevalence of Frailty and Associated Factors in a US-Wide Cohort of Rheumatic Diseases.
Article in ACR open rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Real-world retention of nintedanib and factors associated with treatment discontinuation in connective tissue disease-associated interstitial lung disease: a retrospective cohort study of 92 patients.Clinical rheumatology · 2026Article
- Frailty in rheumatoid arthritis and the general population: a cross-sectional analysis of the Groningen Frailty Indicator and Fried criteria.Rheumatology (Oxford, England) · 2026Article
- Age modifies the prognostic relevance of extracellular water-to-total body water ratio in rheumatoid arthritis: a retrospective cohort study.BMC rheumatology · 2026Article
- Trends in prevalence and disability burden of main rheumatic and musculoskeletal diseases in France 2008-2022.RMD open · 2026Article
- Performance-Based and Self-Reported Frailty in Older Adults with or Without Fibromyalgia.European journal of investigation in health, psychology and education · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectiveWe quantified the prevalence of self-reported frailty and identified associated factors in a US-wide cohort of people with rheumatic and musculoskeletal diseases (RMDs).
methodsFrailty was measured using the FRAIL scale, a patient-reported frailty instrument, in FORWARD, The US-based National Databank for Rheumatic Diseases. Frailty prevalence was determined overall and by individual RMD, which included rheumatoid arthritis, connective tissue diseases (CTDs), osteoarthritis (OA), fibromyalgia, spondyloarthritis (SpA), and vasculitis. Multivariable logistic regression models evaluated the cross-sectional associations between RMDs and frailty, as well as factors associated with frailty within each RMD.
resultsAmong 4,345 individuals, 1,422 were frail (33%). Participants were on average 67.1 ± 11.6 years of age, 82% were female, and 89% self-identified as White. Difficulty with ambulation was the most common frailty feature. With OA as referent, those with CTD had a higher odds of frailty (odds ratio [OR] 1.44, 95% confidence interval [CI] 1.01-2.04), and those with SpA had a lower odds (OR 0.45, 95% CI 0.31-0.67). Age, female sex, pain, disease severity, disease duration, and elevated body mass index categories were all associated with frailty. In the RMD-stratified analyses, disease severity remained associated with frailty in all RMDs except vasculitis.
conclusionFrailty was present in 1 in 3 participants with RMDs, a higher prevalence than estimates from the general population, and primarily manifests as difficulty with mobility. Disease severity was consistently associated with an increased odds of frailty across RMDs. Future interventions to improve physical activity and prevent disease damage may improve frailty status in people with RMDs.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.